MX2021008009A - Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. - Google Patents

Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.

Info

Publication number
MX2021008009A
MX2021008009A MX2021008009A MX2021008009A MX2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A
Authority
MX
Mexico
Prior art keywords
myelodysplastic syndrome
alk5 inhibitors
treating myelodysplastic
alk5
treating
Prior art date
Application number
MX2021008009A
Other languages
English (en)
Inventor
Steven L Warner
David J Bearss
Original Assignee
Sumitomo Pharma Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Oncology Inc filed Critical Sumitomo Pharma Oncology Inc
Publication of MX2021008009A publication Critical patent/MX2021008009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se describen métodos para tratar una enfermedad mediada por ALK5 que incluye síndrome mielodisplásico (MDS), anemia y anemia de enfermedad crónica. También se proporcionan métodos para inhibir la ALK5.
MX2021008009A 2019-01-10 2020-01-10 Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. MX2021008009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962790961P 2019-01-10 2019-01-10
PCT/US2020/013214 WO2020146819A1 (en) 2019-01-10 2020-01-10 Alk5 inhibitors for treating myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
MX2021008009A true MX2021008009A (es) 2021-08-05

Family

ID=71520899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008009A MX2021008009A (es) 2019-01-10 2020-01-10 Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.

Country Status (9)

Country Link
US (2) US20200323851A1 (es)
EP (1) EP3908575A4 (es)
JP (1) JP2022517951A (es)
KR (1) KR20210113314A (es)
CN (1) CN113272281A (es)
AU (1) AU2020207391A1 (es)
CA (1) CA3124714A1 (es)
MX (1) MX2021008009A (es)
WO (1) WO2020146819A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075841A2 (en) * 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
CN103370068A (zh) * 2010-12-03 2013-10-23 Ym生物科学澳大利亚私人有限公司 Jak-2 介导的病症的治疗
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
TR201911151T4 (tr) * 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
TWI582083B (zh) * 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
CA3103995A1 (en) * 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same

Also Published As

Publication number Publication date
US20200323851A1 (en) 2020-10-15
EP3908575A1 (en) 2021-11-17
EP3908575A4 (en) 2022-09-14
US20240075033A1 (en) 2024-03-07
KR20210113314A (ko) 2021-09-15
WO2020146819A1 (en) 2020-07-16
CA3124714A1 (en) 2020-07-16
CN113272281A (zh) 2021-08-17
JP2022517951A (ja) 2022-03-11
AU2020207391A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
EA201890428A1 (ru) Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2018000216A (es) Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
EA201591509A1 (ru) Ингибиторы cdc7
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
PH12017501879A1 (en) Methods for treating cancer
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
BR112017023225A2 (pt) inibidor de proteína cinase
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
PH12017500881A1 (en) Aurora a kinase inhibitor
MX2023011608A (es) Metodos para inhibir ras.
MX2021008009A (es) Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.
MX2018003301A (es) Inhibidores de pcna.
PH12017501880A1 (en) Methods for treating cancer
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
PH12017501881A1 (en) Methods for treating cancer
JOP20150008B1 (ar) أجسام مضادة ل vista وأجزاء منها